Intravenous cyclophosphamide pulse therapy in interstitial lung disease associated with systemic sclerosis in a retrospective open-label study: influence of the extent of inflammation on pulmonary function

Interstitial lung disease (ILD) is the primary cause of death in patients with systemic sclerosis (SSc). It is thought that chronic inflammation is a key component in SSc-ILD. Treatment, such as cyclophosphamide (CYC), targets this inflammation. We hypothesized that treatment with CYC might be more...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Clin Rheumatol
Egile Nagusiak: van den Hombergh, W. M. T., Simons, S. O., Teesselink, E., Knaapen-Hans, H. K. A., van den Hoogen, F. H. J., Fransen, J., Vonk, M. C.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Springer London 2018
Gaiak:
Original Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6154086/
https://ncbi.nlm.nih.gov/pubmed/29987427
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10067-018-4171-6
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak